Marika Russo, PhD, is Market Access Director at Novartis Gene Therapies (former AveXis) Italy and Greece with a key focus on the price and reimbursement process for Zolgensma, the first gene replacement therapy in SMA. Her expertise ranges from market access strategy, evidence generation and value demonstration, health economics, price, policies and reimbursement of advanced therapy medicinal products. In her previous role, she focused in oncology launches moving from onco-hematology to lung cancer in four years at Takeda European headquarter where she worked as Associate Director Europe and Canada.